Vitro Biopharma, Inc. financial data

Location
Denver, CO
Fiscal year end
October 31
Latest financial report
10-Q - Q2 2025 - Sep 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.1 % -82.1%
Quick Ratio 1.2 % -45.3%
Debt-to-equity -145 % +40.4%
Return On Assets -172 % -30.9%
Operating Margin -280 % +41.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.46M shares 0%
Common Stock, Shares, Outstanding 4.46M shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 4.46K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.46M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 4.46M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.11M USD +13.9%
Revenue from Contract with Customer, Excluding Assessed Tax 2.11M USD +13.9%
Research and Development Expense 612K USD +17.4%
Operating Income (Loss) -5.9M USD +33.8%
Net Income (Loss) Attributable to Parent -8.05M USD +17.2%
Earnings Per Share, Basic -1 USD/shares +17.4%
Earnings Per Share, Diluted -1 USD/shares +17.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 206K USD +72.4%
Inventory, Net 174K USD -18.9%
Assets, Current 645K USD -66.6%
Property, Plant and Equipment, Net 57.3K USD -68.2%
Operating Lease, Right-of-Use Asset 256K USD -32.3%
Intangible Assets, Net (Excluding Goodwill) 335K USD -45.7%
Goodwill 3.17M USD -12.1%
Other Assets, Noncurrent 8.44K USD 0%
Assets 4.63M USD -32%
Accounts Payable, Current 2.44M USD +10.7%
Accrued Liabilities, Current 1.86M USD +16.5%
Liabilities, Current 14.9M USD +46.9%
Operating Lease, Liability, Noncurrent 144K USD -43.8%
Liabilities 16.7M USD +18.2%
Retained Earnings (Accumulated Deficit) -44M USD -22.4%
Stockholders' Equity Attributable to Parent -12.1M USD -65%
Liabilities and Equity 4.63M USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -428K USD +64.3%
Net Cash Provided by (Used in) Financing Activities -29.2K USD -101%
Net Cash Provided by (Used in) Investing Activities -74 USD +84.8%
Common Stock, Shares Authorized 19.2M shares 0%
Common Stock, Shares, Issued 4.46M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 175K USD -88.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.22K USD -13.8%
Deferred Tax Assets, Valuation Allowance 7.44M USD +47.3%
Deferred Tax Assets, Gross 7.44M USD +47.3%
Operating Lease, Liability 256K USD -32.3%
Depreciation 124K USD -29.1%
Lessee, Operating Lease, Liability, to be Paid 473K USD -25.6%
Property, Plant and Equipment, Gross 1.06M USD +0.12%
Operating Lease, Liability, Current 112K USD -8.34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 84.6K USD -49.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 167K USD +1.74%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 218K USD -15.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 67.7K USD -19.9%
Deferred Tax Assets, Operating Loss Carryforwards 4.56M USD +48.4%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 67.7K USD 0%
Operating Lease, Payments 40.8K USD -28.4%
Additional Paid in Capital 32M USD +11.5%
Amortization of Intangible Assets 35.7K USD -57.4%
Interest Expense 2.51M USD +1345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%